Krystal Biotech has crossed from launch-stage gene therapy into a self-funding commercial franchise, and the equity now prices a second product that does not yet exist. VYJUVEK, the weekly topical gel that restores collagen seven in dystrophic epidermolysis bullosa wounds, produced all of the second-quarter product sales. Those sales rose to $119 million, a gain of 24 percent from the year-ago quarter. The print is no longer about whether a redosable gene therapy can sell. It is about whether one high-margin orphan gel can keep compounding while the same herpes-simplex vector family earns a second label. Cash and investments sit above $1 billion, so the company does not need the public market to fund the next studies. The market capitalization near $10 billion already treats that next study as more than a scientific hobby.
The second-quarter mix shows why the next stretch of results decides the multiple. United States net sales of $92 million still carry the franchise, helped by more than 730 reimbursement approvals and a community-prescriber push that has already cleared the original sixty percent penetration goal. Overseas volume is a different story. Reported Europe and Japan revenue was broadly flat because management booked a reserve against German list price while statutory talks continue. Underlying vial growth in Germany was in the double digits before that accrual. The mechanism is simple: European payers do not pay United States orphan list prices, and until Germany, Italy, and Spain settle, the international line understates demand and overstates uncertainty. That is the first named thesis variable: realized ex-United States net price.
The second variable is whether weekly persistence holds as some United States patients shift toward start-stop maintenance rather than continuous weekly use. The third is the IOLITE readout on KB803, an eye-drop cousin of VYJUVEK that finished Phase Three enrollment in April and is due before year-end. A clean IOLITE result would be the first commercial-adjacent proof that the HSV-1 platform travels beyond skin wounds using the same plants and the same DEB sales force. A miss would leave Krystal as a richly priced single-product orphan name just as Abeona's surgical graft, Zevaskyn, competes for the largest chronic wounds. At about $339, trailing earnings power near $8 a share already capitalizes a durable franchise plus a pipeline option. The question the rest of the year answers is which of those two the market is actually paying for.